Update from the PERSEUS trial: Patients with newly diagnosed multiple myeloma see improved results with D-VRd induction before #ASCT followed by DR maintenance vs standard induction with VRd, ASCT, and VRd consolidation. #MMSM #SOHO2024 | University of Athens targetedonc.com/view/mrd-negat…
On July 30, 2024, the #FDA approved the daratumumab and hyaluronidase-fihj regimen + bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma eligible for #ASCT. Learn more in this video with Paula Rodriguez-Otero! targetedonc.com/view/behind-th…
Did you hear about last week's #approval of #daratumumab and #hyaluronidase plus #VRd as #ASCT induction and consolidation for newly diagnosed multiple #myeloma (#NDMM)? Read Rahul Banerjee, MD, FACP's perspectives and comment your thoughts below! oncdata.com/daratumumab-an… #MMsm
🚨 En septembre, à #Nantes réserve ta formation pour les cheminots #SNCF avec la #CFDT ✊ Fiche de paie, fiche de paie #ASCT #contractuels, découverte cfdtcheminots Inscription en ligne ouverte 👀 🔗 : docs.google.com/forms/d/e/1FAI…